Vistagen therapeutics stock.

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022. …This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of …Wall Street Stock Market & Finance report, prediction for the future: You'll find the VistaGen Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data VistaGen Therapeutics's VTGN shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).Nov 6, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...

Get a real-time VistaGen Therapeutics, Inc. (VTGN) stock price quote with breaking news, financials, statistics, charts and more.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ...

Vistagen Therapeutics, Inc. (VTGN) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » VTGN Vistagen Therapeutics, Inc. …Vistagen Therapeutics, Inc. 3.6500 +0.0600 +1.67%: TRENDING. 1. ... As U.S. stocks sit on hefty gains at the close of a rollercoaster year, investors are eyeing factors that could sway equities in ...

Based on short-term price targets offered by two analysts, the average price target for VistaGen Therapeutics, Inc. comes to $12.00. The forecasts range from a low of $12.00 to a high of $12.00 ...Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023. 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents ...

Vistagen is requesting approval from its stockholders to have the option to implement a Reverse Split if it becomes necessary to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq and maintain its Nasdaq listing.

Vistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational neuroactive pherine nasal spray in Phase 3 clinical development for acute treatment of social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed novel mechanism of action (MOA) of fasedienol is fundamentally ...

Oct 28, 2022 · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common ... Vistagen Therapeutics, Inc. 3.6900 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...Nov 15, 2022 · The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ... Biotech Firm Pops 677% on Social Anxiety Spray Trial Success. A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits ...William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety ...Find the latest Earnings Report Date for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.

Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.VistaGen Therapeutics stock news, updates & related news. Find out why VistaGen Therapeutics's (VTGN) news sentiment is 12.96% more negative in relation to ...Vistagen Therapeutics Inc. Real-Time Quotes. 3.66. BATS BZX Real-Time Price. As of 2:09pm ET. +0.28 / +8.28%. Today’s Change. 1.62. Today ||| 52-Week Range.What this means: InvestorsObserver gives Vistagen Therapeutics Inc. (VTGN) an overall rank of 48, which is below average. Vistagen Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 48 means that 52% of stocks appear more favorable to our system.Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its ...See today’s best-performing stocks on TipRanks >> Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 ...

The Fast Track designation may expedite development of PH10 for treatment of major depressive disorder in adults SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 6, 2022-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, …2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.

As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ...According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.Founded Date 1998. Founders H. Ralph Snodgrass. Operating Status Active. Last Funding Type Post-IPO Equity. Stock Symbol NASDAQ:VTGN. Company Type For Profit. Contact Email [email protected]. Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to …As of February 7, 2023, the Company had 219,326,526 shares of common stock outstanding, which reflects the issuance of approximately 12.4 million unregistered shares of common stock associated with the Pherin Pharmaceuticals transaction. Conference Call. ... VISTAGEN THERAPEUTICS, INC.Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of …

Vistagen Therapeutics Inc (VTGN) stock has risen 14.79% while the S&P 500 is down -0.56% as of 12:54 PM on Monday, Dec 4. VTGN is up $0.54 from the …

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.05 per share a year ago.

VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700Stock Performance. Shares of VistaGen Therapeutics were trading at $3.475 as of November 07. Over the last 52-week period, shares are down 19.36%.Vistagen Therapeutics. VTGN. $2.57-0.32 (-11.07%) Share Price. as of November 10 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. More on Forbes. ... therapies and ...Dec 1, 2023 · The VistaGen Therapeutics Inc stock price gained 1.67% on the last trading day (Friday, 1st Dec 2023), rising from $3.59 to $3.65. During the last trading day the stock fluctuated 6.05% from a day low at $3.47 to a day high of $3.68. The price has risen in 6 of the last 10 days and is up by 9.94% over the past 2 weeks. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small ...Vistagen Therapeutics. VTGN. $2.57-0.32 (-11.07%) Share Price. as of November 10 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. More on Forbes. ... therapies and ...Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical …VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B ...Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive feedback from its recent engagement with the U.S. Food and Drug Administration (FDA) regarding the …The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Nov 6, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...

The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and...On average, Wall Street analysts predict that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock ...Nov 24, 2023 · 33. Shawn Singh. https://www.vistagen.com. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates ... Instagram:https://instagram. ny state capital gains taxretirement planning groupstock market holiday hoursbest bank stocks to buy today VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) ... Common stock, $0.001 par value; 325,000,000 shares authorized at March 31, 2023 and March 31 ... best mortgage lenders hawaiiamatar As of February 7, 2023, the Company had 219,326,526 shares of common stock outstanding, which reflects the issuance of approximately 12.4 million unregistered shares of common stock associated with the Pherin Pharmaceuticals transaction. Conference Call. ... VISTAGEN THERAPEUTICS, INC. lam research corporation stock Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m. (Simply Wall St.) Sep-20-22 08:30AM. Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit.VistaGen Therapeutics Stock Prediction 2030. In 2030, the VistaGen Therapeutics stock will reach $ 228.74 if it maintains its current 10-year average growth rate. If this VistaGen Therapeutics stock prediction for 2030 materializes, VTGN stock willgrow 6,271.71% from its current price. Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...